FDA postmarket studies for drugs and devices are years overdue
FDA records show hundreds of required follow-up studies for approved drugs and devices are behind schedule, and a pending shift to one-trial approvals leans harder on them.
The FDA has allowed many pharmaceutical companies to delay or ignore required safety and efficacy studies for drugs and devices already on the market, the Washington Post reports. Agency records show that these "postmarket" studies, intended to verify a product's performance after approval, are frequently behind schedule or overdue. The practical effect lands on patients: people may use medications such as the autoimmune drug Tavneos without the full safety data agency experts originally requested.
A separate analysis of FDA data, reported by Government Executive, found that hundreds of required postmarket studies for drugs and medical devices are running behind schedule, and that many manufacturers have failed to complete follow-up research mandated years after product approval. KFF Health News, which published its own examination of the same records, framed the mechanism plainly: the FDA has allowed companies to sell drugs and devices while they complete safety and efficacy studies, and many of those postmarket requirements are now overdue or behind schedule. All three accounts converge on the same record — approved products, unfinished research, and patients in the gap.
The approval bargain the studies are supposed to close
Postmarket studies are not an afterthought. They are the second half of a bargain. A product reaches the market on the strength of preapproval evidence; the follow-up research confirms that the performance seen in trials holds up in wider use, where the population is larger, older, and more complicated than any trial cohort.
That bargain is about to carry more weight. FDA leaders announced in February that the default requirement for agency approvals will shift to one clinical trial instead of two, according to KFF Health News. Fewer preapproval trials means more of the safety and effectiveness picture has to be assembled after the product is already being sold. The shift increases reliance on postmarket studies to ensure patient safety, and it moves more risk onto users if companies fail to finish the research they owe.
The three reports point in the same direction: the postmarket side of that bargain is the side that keeps slipping.
What the record shows
Source
Account
Tags
mindfulness
Share
The Washington Post
FDA has allowed many companies to delay or ignore required safety and efficacy studies for drugs and devices already on the market
Government Executive
An analysis found hundreds of required postmarket studies are running behind schedule, with many manufacturers failing to complete mandated follow-up research years after approval
KFF Health News
Many postmarket requirements are now overdue or behind schedule, while the agency moves to a one-trial default for approvals
The Washington Post notes that agency records show the studies are frequently behind schedule or overdue, and that patients may use medications such as Tavneos without the full safety data originally requested by agency experts. Government Executive says the delays hinder the FDA's ability to monitor long-term safety and effectiveness, potentially leaving patients exposed to undetected side effects. KFF Health News adds that the burden of that incompleteness rises as preapproval requirements loosen.
None of the three accounts disputes the value of the studies or claims the agency has no authority to demand them. The dispute is about completion — what happens between a requirement being set and the research arriving.
Unfinished research is not the only line on the same ledger
The same week, health coverage turned repeatedly to the distance between a policy announcement and the outcome it promises.
Statnews reports that Robert F. Kennedy Jr. is scheduled to speak at a conference hosted by the Children's Health Defense organization, part of a broader series of health news updates that also includes research on protecting heart health in outer space. The item sits alongside the FDA studies story on the same morning rounds, a reminder that the question of who sets medical guidance, and how strictly it is followed, is live on multiple fronts.
On vaccines, CIDRAP reports that the U.S. Food and Drug Administration approved this season's COVID vaccines nearly three weeks ago for general use. Children with private insurance can currently access the shots, but those in the Vaccines for Children program must wait for Health and Human Services sign-off — a delay that affects about half of the country's children who rely on the program because they are uninsured, underinsured, Medicaid-eligible, or American Indian or Alaska Native. CIDRAP's state-of-vaccine-policy roundup also notes four measles deaths and a looming policy comment deadline.
In Philadelphia, health officials reported a potential measles exposure at the Children's Hospital of Philadelphia on September 11, according to the Inquirer. The exposure occurred in the neonatal intensive care unit and other locations at the hospital's 3401 Civic Center Blvd facility, during a larger measles outbreak in Pennsylvania that has sickened nearly 700 people.
A different disease, a harder curve
Abroad, the World Health Organization reported on September 10 that the Democratic Republic of the Congo is experiencing the fastest-growing Ebola outbreak on record, per the George W. Bush Presidential Center's global health update. Health officials have confirmed more than 6,700 cases and more than 3,200 deaths during the current surge.
That update also tracks a funding line: approximately $1.4 billion is currently available or nearing award for nutrition, disease surveillance, and health programs in Cameroon, Côte d'Ivoire, and Mozambique — resources described as critical support for countries struggling to manage infectious diseases and basic nutritional needs.
Read against the FDA reporting, the pairing is instructive. The Ebola surge is a case where surveillance and funding are the levers, and where the record is measured in cases and deaths. The postmarket studies are a case where the levers are already in place — the agency ordered the research — and the outcome is measured in whether it arrives.
Reuters' health news summary carried one more instance of the same theme. Xenon Pharmaceuticals paused new patient enrollment in clinical trials for its experimental major and bipolar depression drug on Thursday, the company halting the studies following reports of side effects related to the mental and nervous system. Xenon shares fell more than 25% in after-hours trading as a result of the trial pause. It is the mirror image of the postmarket problem: here, the signal arrived mid-study and the company stopped. The FDA records describe what happens when the signal is expected after the study, and the study keeps slipping.
Where the delay actually bites
For a patient on Tavneos or any other product with an overdue postmarket requirement, the practical difference between a completed study and a pending one is whether the safety profile they are relying on has been confirmed by the research the agency itself asked for. That is the standard the Washington Post, Government Executive, and KFF Health News all applied to the same set of records.
The FDA's February decision to make one trial the default for approvals does not create the postmarket gap. It raises the stakes of closing it. If the required studies are frequently behind schedule or overdue now, and the preapproval evidence is set to shrink, then the follow-up research becomes the load-bearing part of the safety case rather than a supplement to it.
Nothing in the reporting suggests manufacturers are unable to do the work; what the records show is that many have not. The agency approved the products. The agency ordered the studies. Years later, the studies are still not done.